Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor–Induced Thyroiditis

Reduced Tumor Size of Untreated Papillary Thyroid Carcinoma After Immune Checkpoint Inhibitor–Induced Thyroiditis

Background/Objective: Immune checkpoint inhibitors (CPIs) activate antitumoral immune responses and are used to treat multiple types of primary and metastatic malignancies. Thyroid dysfunction is a known immune-related adverse event of CPI therapy. There are few data on the effect of CPI and CPI-ind...

Full description

Bibliographic Details
Main Authors: Dennis H. Chen, MD, Heinz-Josef Lenz, MD, Melissa G. Lechner, MD/PhD, Trevor E. Angell, MD
Format: Article
Language:English
Published: Elsevier 2023-09-01
Series:AACE Clinical Case Reports
Subjects:
papillary thyroid carcinoma
immune checkpoint inhibitors
immune-related adverse events
efficacy
thyroiditis
Online Access:http://www.sciencedirect.com/science/article/pii/S2376060523001153

Similar Items

Similar Items